Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation

被引:12
|
作者
Webster-Clark, Michael [1 ]
Lund, Jennifer L. [1 ]
Sturmer, Til [1 ]
Poole, Charles [1 ]
Simpson, Ross J. [2 ]
Edwards, Jessie K. [1 ]
机构
[1] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA
基金
美国国家卫生研究院;
关键词
Anticoagulation; Generalizability; Medicare; Older adults; Transportability; CLINICAL-TRIALS; ORAL ANTICOAGULANTS; STROKE PREVENTION; ADVERSE EVENTS; WARFARIN; DABIGATRAN; RIVAROXABAN; APIXABAN; OUTCOMES; THERAPY;
D O I
10.1097/EDE.0000000000001230
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Results from trials and nonexperimental studies are often directly compared, with little attention paid to differences between study populations. When target and trial population data are available, accounting for these differences through transporting trial results to target populations of interest provides useful perspective. We aimed to compare two-year risk differences (RDs) for ischemic stroke, mortality, and gastrointestinal bleeding in older adults with atrial fibrillation initiating dabigatran and warfarin when using trial transport methods versus nonexperimental methods. Methods: We identified Medicare beneficiaries who initiated warfarin or dabigatran from a 20% nationwide sample. To transport treatment effects observed in the randomized evaluation of long-term anticoagulation trial, we applied inverse odds weights to standardize estimates to two Medicare target populations of interest, initiators of: (1) dabigatran and (2) warfarin. Separately, we conducted a nonexperimental study in the Medicare populations using standardized morbidity ratio weighting to control measured confounding. Results: Comparing dabigatran to warfarin, estimated two-year RDs for ischemic stroke were similar with trial transport and nonexperimental methods. However, two-year mortality RDs were closer to the null when using trial transport versus nonexperimental methods for the dabigatran target population (transported RD: -0.57%; nonexperimental RD: -1.9%). Estimated gastrointestinal bleeding RDs from trial transport (dabigatran initiator RD: 1.8%; warfarin initiator RD: 1.9%) appeared more harmful than nonexperimental results (dabigatran initiator RD: 0.14%; warfarin initiator RD: 0.57%). Conclusions: Differences in study populations can and should be considered quantitatively to ensure results are relevant to populations of interest, particularly when comparing trial with nonexperimental findings. See video abstract:.
引用
收藏
页码:605 / 613
页数:9
相关论文
共 50 条
  • [41] DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION PATIENTS WITH LOW, MODERATE AND HIGH CHADS2 SCORE: A RE-LY SUBGROUP ANALYSIS
    Oldgren, Jonas
    Alings, Marco
    Darius, Harald
    Eikelboom, John
    Ezekowitz, Michael
    Parekh, Amit
    Pogue, Janice
    Reilly, Paul
    Yusuf, Salim
    Wallentin, Lars
    Connolly, Stuart
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [42] Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis
    Hijazi, Ziad
    Hohnloser, Stefan H.
    Oldgren, Jonas
    Andersson, Ulrika
    Connolly, Stuart J.
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Siegbahn, Agneta
    Yusuf, Salim
    Wallentin, Lars
    CIRCULATION, 2014, 129 (09) : 961 - 970
  • [44] Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial
    Hori, Masatsugu
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Yusuf, Salim
    Wallentin, Lars
    CIRCULATION JOURNAL, 2011, 75 (04) : 800 - 805
  • [45] Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy
    Hijazi, Ziad
    Oldgren, Jonas
    Andersson, Ulrika
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Hohnloser, Stefan H.
    Reilly, Paul A.
    Vinereanu, Dragos
    Siegbahn, Agneta
    Yusuf, Salim
    Wallentin, Lars
    CIRCULATION, 2012, 125 (13) : 1605 - U71
  • [46] Letter by Stollberger and Finsterer Regarding Article, "Intracranial Hemorrhage in Patients With Atrial Fibrillation During Anticoagulation With Warfarin or Dabigatran: The Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial"
    Stoellberger, Claudia
    Finsterer, Josef
    STROKE, 2012, 43 (09) : E93 - E93
  • [47] Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial
    Liesenfeld, K-H
    Lehr, T.
    Dansirikul, C.
    Reilly, P. A.
    Connolly, S. J.
    Ezekowitz, M. D.
    Yusuf, S.
    Wallentin, L.
    Haertter, S.
    Staab, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (11) : 2168 - 2175
  • [48] Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis
    Hijazi, Ziad
    Hohnloser, Stefan H.
    Oldgren, Jonas
    Andersson, Ulrika
    Connolly, Stuart J.
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Yusuf, Salim
    Wallentin, Lars
    AMERICAN HEART JOURNAL, 2018, 198 : 169 - 177
  • [49] Efficacy and Safety of Dabigatran Compared With Warfarin in Patients With Atrial Fibrillation and Normal Renal Function Over Time: Insights From the RE-LY Trial
    Hijazi, Ziad
    Hohnloser, Stefan H.
    Oldgren, Jonas
    Andersson, Ulrika
    Connolly, Stuart J.
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Yusuf, Salim
    Wallentin, Lars
    CIRCULATION, 2015, 132
  • [50] Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials
    Hijazi, Ziad
    Oldgren, Jonas
    Lindback, Johan
    Alexander, John H.
    Alings, Marco
    De Caterina, Raffaele
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Held, Claes
    Huber, Kurt
    Hylek, Elaine M.
    Granger, Christopher B.
    Lopes, Renato D.
    Vinereanu, Dragos
    Siegbahn, Agneta
    Wallentin, Lars
    JAMA NETWORK OPEN, 2020, 3 (09)